T. Rowe Price Investment Management
APGE icon

T. Rowe Price Investment Management’s Apogee Therapeutics APGE Stock Holding History

T. Rowe Price Investment Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101M Sell
762,183
-9,538,801
-93% -$859M 0.07% 268
2026
Q1 		$867M Buy
10,300,984
+7,568,528
+277% +$550M 0.6% 36
2025
Q4 		$206M Buy
2,732,456
+2,731,015
+189,522% +$172M 0.13% 166
2025
Q3 		$58K Buy
1,441
+977
+211% +$37.3K ﹤0.01% 662
2025
Q2 		$21K Buy
+464
New +$17.7K ﹤0.01% 673

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

T. Rowe Price Investment Management's APGE Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Apogee Therapeutics (APGE) stake by 93% in Q2 2026, selling an estimated $859M and leaving 762,183 shares worth $101M. The position accounts for 0.07% of the portfolio, ranked #268.

T. Rowe Price Investment Management first reported a position in APGE in Q2 2025 and has held it in 5 quarters since. The position peaked at $867M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • T. Rowe Price Investment Management held 762,183 shares of Apogee Therapeutics worth $101M as of Q2 2026.
  • T. Rowe Price Investment Management sold 9,538,801 Apogee Therapeutics shares in Q2 2026, an estimated $859M.
  • Apogee Therapeutics made up 0.07% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #268 holding.
  • T. Rowe Price Investment Management first reported a position in Apogee Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • T. Rowe Price Investment Management's Apogee Therapeutics position peaked at $867M in Q1 2026.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.